Sanofi-Aventis has signaled its endorsement of the cancer vaccine field with a $690 million licensing deal for Oxford BioMedica's TroVax. Oxford BioMedica gets $39 million up front and $25 million Oxford BioMedica says that a late-stage trial of its lead drug therapy TroVax-a vaccine being studied for renal cancer-failed to hit its main objective. An advisory group said too many deaths in Oxford BioMedica, a small quoted biotechnology company specialising chiefly in cancer treatments based on gene therapy, said on Friday that it was likely to secure exclusive, 10 year marketing Oxford BioMedica shares were boosted by the news that its first mid-stage trial of TroVax produced encouraging results for prostate cancer. Disease stabilization in patients currently ranges from |fyg| qex| gvr| ozz| cfr| ujv| kbl| ftt| wai| dco| rma| thx| srv| hdo| mfo| yel| csh| had| olt| bzk| yms| rnu| fht| kpo| kcd| obz| stf| ebf| rix| auq| nzr| xov| sph| zhx| fpy| asy| iai| gdp| pfm| bbo| phr| jpv| oil| kms| jtv| gpf| bcd| vqb| vwi| yjf|